Physician profile
Moises Haratz
NPI 1013183805
$1,492.93
in general payments reported to CMS, 2019-2025
24 companies · $357 in 2025
The $357 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $71.32 · 2021: $114 · 2022: $137 · 2023: $263 · 2024: $318 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918 · Long Term Medical Supply Or Device Loan: $19.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.90 |
| Long Term Medical Supply Or Device Loan | $19.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $167.31 | 2019-2025 | Doc Band |
| Sanofi Pasteur INC. | $152.86 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $134.64 | 2019-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Alk-Abello, INC | $127.25 | 2023-2025 | Grastek, Ragwitek, Odactra |
| Kaleo, INC. | $110.32 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $101.19 | 2020-2025 | Dupixent |
| Sobi, INC | $88.68 | 2021-2023 | |
| Pfizer INC. | $77.21 | 2019-2021 | |
| Biomarin Pharmaceutical INC. | $57.29 | 2025 | Voxzogo 1.2mg |
| Amgen INC. | $57.08 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.46 | 2024 | Eohilia |
| Cipher Pharmaceuticals US LLC | $43.68 | 2025 | Natroba, Spinosad |
| Sanofi-Aventis U.S. LLC | $43.59 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $39.92 | 2025 | Neffy |
| Aytu Biopharma, INC. | $39.02 | 2024 | Karbinal |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $35.00 | 2019-2021 | |
| Glaxosmithkline, LLC. | $30.29 | 2023 | Nucala |
| Greer Laboratories, INC. | $23.85 | 2025 | Oralair |
| Novartis Pharmaceuticals Corporation | $23.59 | 2024 | |
| Genentech USA, INC. | $21.01 | 2024 | Xolair |
| Baxter Healthcare | $19.41 | 2023 | Hillrom - Cp 150 Resting Electrocardiograph |
| Aimmune Therapeutics, INC. | $17.98 | 2020 | |
| Amneal Pharmaceuticals LLC | $15.94 | 2019 | |
| Phadia US INC. | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moises Haratz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.